^
Association details:
| Biomarker: | RET rearrangement |
|---|---|
| Cancer: | Thyroid Gland Carcinoma |
| Drug: | Koselugo (selumetinib) (MEK inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
AZD1480 Blocks Growth and Tumorigenesis of RET- Activated Thyroid Cancer Cell Lines
Excerpt:
AZD1480 inhibited the growth of all RET-mutated/rearranged cell lines after 1 (MZ-CRC1, TT) and 2 days (TPC-1) of treatment (p<0.0001; Fig.1A) and minimally decreased the growth of C643,...We observed that AZD6244 minimally decreased the growth of C643 and MZ-CRC1 after 4/5 days of treatment (p<0.001; Fig. 1A and S1)...and decreased TPC-1 growth by 50% after 5 days of treatment. In contrast, AZD6244 efficiently inhibited the growth of BRAF- mutant K1 cell line (Fig. S1).
DOI:
10.1371/journal.pone.0046869
